NCT07899801
A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)
StatusNot Yet Recruiting
PhasePhase 1
SponsorM.D. Anderson Cancer Center
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Safety and Adverse Events (AEs)
Timeframe: Through study completion; an average of 1 year
Arms and interventions
Part 1 Safety Lead-In Cohort: Treatment with Zanidatamab + ZongertinibExperimental
Participants will receive treatment on an outpatient basis
Part 2 Expansion Cohort: Treatment with Zanidatamab + ZongertinibExperimental
Participants will receive treatment on an outpatient basis
Drugs: Zanidatamab, Zongertinib
Sites
1 site in 1 country
- UT MD AndersonHouston, Texas, United States